Online inquiry

IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6659MR)

This product GTTS-WQ6659MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6659MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3100MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ1816MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ5295MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ11949MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ10661MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ12439MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ9760MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ1792MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW